Serveur d'exploration sur les pandémies grippales

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Safety profile of oseltamivir during the 2009 influenza pandemic

Identifieur interne : 002721 ( Main/Curation ); précédent : 002720; suivant : 002722

Safety profile of oseltamivir during the 2009 influenza pandemic

Auteurs : Barbara Donner [Suisse] ; Silvia Bader-Weder [Suisse] ; Roman Schwarz [Suisse] ; Michael M. Peng [États-Unis] ; James Robert Smith [Suisse] ; Viswanathan Niranjan [Inde]

Source :

RBID : ISTEX:8BEC19A66A04D924EF5D77CF833E59AF1387E7D3

Descripteurs français

English descriptors

Abstract

Purpose: This study evaluated the safety of oseltamivir during the 2009 influenza pandemic. Methods: Case reports were obtained from the Roche safety database. The incidence of adverse events (AEs) during the pandemic (1 May 2009 to 31 December 2009) was compared with that beforehand (during previous influenza seasons) for USA and Japan only, as exposure data in other countries were collected inconsistently. Events with significantly higher reporting during the pandemic (lower bound of 95%CI for crude rate ratio >1) were analyzed further. Results: Global exposure in the pandemic and prepandemic periods was 18.3 and 64.7 million patients, respectively. In USA and Japan, exposure was 15.5 (1382 cases, 2225 events) and 62.0 million (8387 cases, 12 749 events), respectively. AEs with significantly higher reporting during the pandemic were generally consistent with influenza and its complications and/or with the circulation of a novel virus strain. As might be expected in a pandemic, mortality increased (crude rate ratio, 2.83; 95%CI, 2.23–3.59) versus the prepandemic period. Medical review of serious AEs (fatal or non‐fatal outcome) found that most were consistent with pre‐existing risk factors, underlying disease, and/or progression of influenza or its complications. Analysis of the remainder did not suggest a causal link with oseltamivir. A review of AEs in previously underexposed subpopulations did not support an association with oseltamivir. Conclusions: During the first 8 months of the 2009 influenza pandemic, AEs reported in patients exposed to oseltamivir were consistent with the drug's labeled safety profile, underlying medical conditions, or infection with the pandemic virus. Copyright © 2011 John Wiley & Sons, Ltd.

Url:
DOI: 10.1002/pds.2136

Links toward previous steps (curation, corpus...)


Links to Exploration step

ISTEX:8BEC19A66A04D924EF5D77CF833E59AF1387E7D3

Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Safety profile of oseltamivir during the 2009 influenza pandemic</title>
<author>
<name sortKey="Donner, Barbara" sort="Donner, Barbara" uniqKey="Donner B" first="Barbara" last="Donner">Barbara Donner</name>
</author>
<author>
<name sortKey="Bader Eder, Silvia" sort="Bader Eder, Silvia" uniqKey="Bader Eder S" first="Silvia" last="Bader-Weder">Silvia Bader-Weder</name>
</author>
<author>
<name sortKey="Schwarz, Roman" sort="Schwarz, Roman" uniqKey="Schwarz R" first="Roman" last="Schwarz">Roman Schwarz</name>
</author>
<author>
<name sortKey="Peng, Michael M" sort="Peng, Michael M" uniqKey="Peng M" first="Michael M." last="Peng">Michael M. Peng</name>
</author>
<author>
<name sortKey="Smith, James Robert" sort="Smith, James Robert" uniqKey="Smith J" first="James Robert" last="Smith">James Robert Smith</name>
</author>
<author>
<name sortKey="Niranjan, Viswanathan" sort="Niranjan, Viswanathan" uniqKey="Niranjan V" first="Viswanathan" last="Niranjan">Viswanathan Niranjan</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:8BEC19A66A04D924EF5D77CF833E59AF1387E7D3</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1002/pds.2136</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-M5N0NWHF-X/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000983</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000983</idno>
<idno type="wicri:Area/Istex/Curation">000983</idno>
<idno type="wicri:Area/Istex/Checkpoint">000941</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000941</idno>
<idno type="wicri:doubleKey">1053-8569:2011:Donner B:safety:profile:of</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:21448900</idno>
<idno type="wicri:Area/PubMed/Corpus">001052</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001052</idno>
<idno type="wicri:Area/PubMed/Curation">001052</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001052</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000E56</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000E56</idno>
<idno type="wicri:Area/Ncbi/Merge">001006</idno>
<idno type="wicri:Area/Ncbi/Curation">001006</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001006</idno>
<idno type="wicri:Area/Main/Merge">002818</idno>
<idno type="wicri:Area/Main/Curation">002721</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main">Safety profile of oseltamivir during the 2009 influenza pandemic</title>
<author>
<name sortKey="Donner, Barbara" sort="Donner, Barbara" uniqKey="Donner B" first="Barbara" last="Donner">Barbara Donner</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>F. Hoffmann‐La Roche Ltd, Basel</wicri:regionArea>
<wicri:noRegion>Basel</wicri:noRegion>
</affiliation>
<affiliation></affiliation>
<affiliation></affiliation>
</author>
<author>
<name sortKey="Bader Eder, Silvia" sort="Bader Eder, Silvia" uniqKey="Bader Eder S" first="Silvia" last="Bader-Weder">Silvia Bader-Weder</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>F. Hoffmann‐La Roche Ltd, Basel</wicri:regionArea>
<wicri:noRegion>Basel</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Schwarz, Roman" sort="Schwarz, Roman" uniqKey="Schwarz R" first="Roman" last="Schwarz">Roman Schwarz</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>F. Hoffmann‐La Roche Ltd, Basel</wicri:regionArea>
<wicri:noRegion>Basel</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Peng, Michael M" sort="Peng, Michael M" uniqKey="Peng M" first="Michael M." last="Peng">Michael M. Peng</name>
<affiliation wicri:level="1">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Hoffmann‐La Roche, Inc., NJ, Nutley</wicri:regionArea>
<wicri:noRegion>Nutley</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Smith, James Robert" sort="Smith, James Robert" uniqKey="Smith J" first="James Robert" last="Smith">James Robert Smith</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>F. Hoffmann‐La Roche Ltd, Basel</wicri:regionArea>
<wicri:noRegion>Basel</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Niranjan, Viswanathan" sort="Niranjan, Viswanathan" uniqKey="Niranjan V" first="Viswanathan" last="Niranjan">Viswanathan Niranjan</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Inde</country>
<wicri:regionArea>RxMD, Chennai</wicri:regionArea>
<wicri:noRegion>Chennai</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j" type="main">Pharmacoepidemiology and Drug Safety</title>
<title level="j" type="alt">PHARMACOEPIDEMIOLOGY AND DRUG SAFETY</title>
<idno type="ISSN">1053-8569</idno>
<idno type="eISSN">1099-1557</idno>
<imprint>
<biblScope unit="vol">20</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="532">532</biblScope>
<biblScope unit="page" to="543">543</biblScope>
<biblScope unit="page-count">12</biblScope>
<publisher>John Wiley & Sons, Ltd</publisher>
<pubPlace>Chichester, UK</pubPlace>
<date type="published" when="2011-05">2011-05</date>
</imprint>
<idno type="ISSN">1053-8569</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">1053-8569</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adult</term>
<term>Adverse Drug Reaction Reporting Systems</term>
<term>Aged</term>
<term>Antiviral Agents (administration & dosage)</term>
<term>Antiviral Agents (adverse effects)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Female</term>
<term>Humans</term>
<term>Infant</term>
<term>Infant, Newborn</term>
<term>Influenza, Human (drug therapy)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Japan (epidemiology)</term>
<term>Male</term>
<term>Medication Errors (statistics & numerical data)</term>
<term>Middle Aged</term>
<term>Oseltamivir (administration & dosage)</term>
<term>Oseltamivir (adverse effects)</term>
<term>Oseltamivir (therapeutic use)</term>
<term>Pandemics (prevention & control)</term>
<term>Pandemics (statistics & numerical data)</term>
<term>United States (epidemiology)</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Antiviraux (administration et posologie)</term>
<term>Antiviraux (effets indésirables)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Erreurs de médication ()</term>
<term>Femelle</term>
<term>Grippe humaine (traitement médicamenteux)</term>
<term>Grippe humaine (épidémiologie)</term>
<term>Humains</term>
<term>Japon (épidémiologie)</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Nourrisson</term>
<term>Nouveau-né</term>
<term>Oséltamivir (administration et posologie)</term>
<term>Oséltamivir (effets indésirables)</term>
<term>Oséltamivir (usage thérapeutique)</term>
<term>Pandémies ()</term>
<term>Sujet âgé</term>
<term>Systèmes de signalement des effets indésirables des médicaments</term>
<term>États-Unis d'Amérique (épidémiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Antiviral Agents</term>
<term>Oseltamivir</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en">
<term>Antiviral Agents</term>
<term>Oseltamivir</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Antiviral Agents</term>
<term>Oseltamivir</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en">
<term>Japan</term>
<term>United States</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr">
<term>Antiviraux</term>
<term>Oséltamivir</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr">
<term>Antiviraux</term>
<term>Oséltamivir</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en">
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en">
<term>Pandemics</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en">
<term>Medication Errors</term>
<term>Pandemics</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Antiviraux</term>
<term>Oséltamivir</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr">
<term>Grippe humaine</term>
<term>Japon</term>
<term>États-Unis d'Amérique</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en">
<term>Abnormal behavior</term>
<term>Adult</term>
<term>Adverse Drug Reaction Reporting Systems</term>
<term>Adverse events</term>
<term>Aged</term>
<term>Antiviral medications</term>
<term>Birth defects</term>
<term>Causal link</term>
<term>Causal relationship</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Clin drug investig</term>
<term>Clinical aspects</term>
<term>Clinical features</term>
<term>Clinical trials</term>
<term>Concomitant medications</term>
<term>Confidence interval</term>
<term>Consumer reports</term>
<term>Copyright</term>
<term>Countries exposure cases</term>
<term>Crude incidence rates</term>
<term>Crude rate ratio</term>
<term>Database</term>
<term>Disease control</term>
<term>Disease progression</term>
<term>Distress syndrome</term>
<term>Donner</term>
<term>Drug safety</term>
<term>Elderly subpopulation</term>
<term>Elsevier saunders</term>
<term>Engl</term>
<term>Esophageal carcinoma</term>
<term>Euro surveill</term>
<term>Events hepatic failure</term>
<term>Events rate</term>
<term>Fatal cases</term>
<term>Fatal outcome</term>
<term>Fatal outcomes</term>
<term>Febrile seizures</term>
<term>Female</term>
<term>Fourth case</term>
<term>Gastrointestinal hemorrhage</term>
<term>General signs</term>
<term>Health care</term>
<term>Health care professionals</term>
<term>Healthcare products</term>
<term>Higher level terms</term>
<term>Hlts</term>
<term>Humans</term>
<term>Immunocompromised</term>
<term>Immunocompromised patients</term>
<term>Immunocompromised status</term>
<term>Infant</term>
<term>Infant, Newborn</term>
<term>Infection</term>
<term>International conference</term>
<term>Japan exposure cases</term>
<term>John wiley sons</term>
<term>Large increase</term>
<term>Lower level terms</term>
<term>Male</term>
<term>Mcgraw hill</term>
<term>Medical history</term>
<term>Medical information</term>
<term>Medical review</term>
<term>Medication</term>
<term>Medication errors</term>
<term>Middle Aged</term>
<term>Myocarditis</term>
<term>Neuraminidase</term>
<term>Oseltamivir</term>
<term>Oseltamivir phosphate</term>
<term>Oseltamivir treatment</term>
<term>Other countries</term>
<term>Pandemic</term>
<term>Pandemic period</term>
<term>Patient exposure</term>
<term>Patient subpopulations</term>
<term>Pharmacoepidemiology</term>
<term>Preferred terms</term>
<term>Pregnancy exposure</term>
<term>Pregnant women</term>
<term>Prepandemic</term>
<term>Prepandemic period</term>
<term>Prepandemic periods</term>
<term>Prophylaxis</term>
<term>Pulmonary disease</term>
<term>Respiratory complications</term>
<term>Respiratory failure</term>
<term>Risk factor</term>
<term>Risk factors</term>
<term>Roche</term>
<term>Roche safety database</term>
<term>Saes</term>
<term>Safety database</term>
<term>Serious events</term>
<term>Spontaneous abortion</term>
<term>Spontaneous reports</term>
<term>Subpopulation</term>
<term>Supplementary data</term>
<term>Supplementary table</term>
<term>Supplementary tables</term>
<term>Technical requirements</term>
<term>Therapeutic abortion</term>
<term>Ventricular arrhythmia</term>
<term>Virus infection</term>
<term>World health organization</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Erreurs de médication</term>
<term>Femelle</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Nourrisson</term>
<term>Nouveau-né</term>
<term>Pandémies</term>
<term>Sujet âgé</term>
<term>Systèmes de signalement des effets indésirables des médicaments</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr">
<term>Japon</term>
<term>États-Unis</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract">Purpose: This study evaluated the safety of oseltamivir during the 2009 influenza pandemic. Methods: Case reports were obtained from the Roche safety database. The incidence of adverse events (AEs) during the pandemic (1 May 2009 to 31 December 2009) was compared with that beforehand (during previous influenza seasons) for USA and Japan only, as exposure data in other countries were collected inconsistently. Events with significantly higher reporting during the pandemic (lower bound of 95%CI for crude rate ratio >1) were analyzed further. Results: Global exposure in the pandemic and prepandemic periods was 18.3 and 64.7 million patients, respectively. In USA and Japan, exposure was 15.5 (1382 cases, 2225 events) and 62.0 million (8387 cases, 12 749 events), respectively. AEs with significantly higher reporting during the pandemic were generally consistent with influenza and its complications and/or with the circulation of a novel virus strain. As might be expected in a pandemic, mortality increased (crude rate ratio, 2.83; 95%CI, 2.23–3.59) versus the prepandemic period. Medical review of serious AEs (fatal or non‐fatal outcome) found that most were consistent with pre‐existing risk factors, underlying disease, and/or progression of influenza or its complications. Analysis of the remainder did not suggest a causal link with oseltamivir. A review of AEs in previously underexposed subpopulations did not support an association with oseltamivir. Conclusions: During the first 8 months of the 2009 influenza pandemic, AEs reported in patients exposed to oseltamivir were consistent with the drug's labeled safety profile, underlying medical conditions, or infection with the pandemic virus. Copyright © 2011 John Wiley & Sons, Ltd.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002721 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 002721 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     ISTEX:8BEC19A66A04D924EF5D77CF833E59AF1387E7D3
   |texte=   Safety profile of oseltamivir during the 2009 influenza pandemic
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021